BNP Paribas Financial Markets’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $713K | Sell |
32,601
-7,780
| -19% | -$162K | ﹤0.01% | 3551 |
|
|
2026
Q1 | $943K | Buy |
40,381
+26,153
| +184% | +$568K | ﹤0.01% | 3171 |
|
|
2025
Q4 | $299K | Sell |
14,228
-585,643
| -98% | -$10.2M | ﹤0.01% | 3863 |
|
|
2025
Q3 | $9.23M | Buy |
599,871
+99,968
| +20% | +$1.31M | ﹤0.01% | 1594 |
|
|
2025
Q2 | $4.68M | Buy |
499,903
+282,910
| +130% | +$3.11M | ﹤0.01% | 1901 |
|
|
2025
Q1 | $2.67M | Sell |
216,993
-42,252
| -16% | -$596K | ﹤0.01% | 2178 |
|
|
2024
Q4 | $3.43M | Buy |
259,245
+238,146
| +1,129% | +$4.08M | ﹤0.01% | 2033 |
|
|
2024
Q3 | $406K | Buy |
21,099
+16,663
| +376% | +$344K | ﹤0.01% | 2947 |
|
|
2024
Q2 | $91.1K | Sell |
4,436
-41,166
| -90% | -$862K | ﹤0.01% | 3315 |
|
|
2024
Q1 | $1.09M | Sell |
45,602
-117,303
| -72% | -$2.62M | ﹤0.01% | 2444 |
|
|
2023
Q4 | $3.52M | Buy |
162,905
+44,906
| +38% | +$690K | ﹤0.01% | 1624 |
|
|
2023
Q3 | $1.71M | Buy |
117,999
+47,846
| +68% | +$905K | ﹤0.01% | 1977 |
|
|
2023
Q2 | $1.47M | Sell |
70,153
-45,537
| -39% | -$948K | ﹤0.01% | 1950 |
|
|
2023
Q1 | $2.44M | Buy |
115,690
+59,878
| +107% | +$1.49M | ﹤0.01% | 1682 |
|
|
2022
Q4 | $1.42M | Sell |
55,812
-10,465
| -16% | -$244K | ﹤0.01% | 1964 |
|
|
2022
Q3 | $1.59M | Buy |
66,277
+53,665
| +426% | +$1.2M | ﹤0.01% | 2133 |
|
|
2022
Q2 | $243K | Sell |
12,612
-25,247
| -67% | -$421K | ﹤0.01% | 3002 |
|
|
2022
Q1 | $658K | Sell |
37,859
-30,540
| -45% | -$514K | ﹤0.01% | 2596 |
|
|
2021
Q4 | $1.5M | Buy |
68,399
+57,779
| +544% | +$1.07M | ﹤0.01% | 2283 |
|
|
2021
Q3 | $203K | Buy |
10,620
+7,502
| +241% | +$125K | ﹤0.01% | 3035 |
|
|
2021
Q2 | $53.5K | Sell |
3,118
-8,629
| -73% | -$158K | ﹤0.01% | 3236 |
|
|
2021
Q1 | $263K | Sell |
11,747
-82,973
| -88% | -$1.87M | ﹤0.01% | 2911 |
|
|
2020
Q4 | $2.11M | Buy |
94,720
+88,451
| +1,411% | +$1.83M | ﹤0.01% | 1607 |
|
|
2020
Q3 | $92.5K | Buy |
6,269
+4,171
| +199% | +$63.6K | ﹤0.01% | 3160 |
|
|
2020
Q2 | $31.1K | Sell |
2,098
-4,351
| -67% | -$66.3K | ﹤0.01% | 3224 |
|
|
2020
Q1 | $70.7K | Buy |
6,449
+3,661
| +131% | +$34.4K | ﹤0.01% | 3382 |
|
|
2019
Q4 | $24.5K | Buy |
2,788
+236
| +9% | +$1.73K | ﹤0.01% | 3942 |
|
|
2019
Q3 | $19.1K | Buy |
2,552
+904
| +55% | +$8.23K | ﹤0.01% | 3967 |
|
|
2019
Q2 | $15.3K | Sell |
1,648
-1,514
| -48% | -$11K | ﹤0.01% | 3991 |
|
|
2019
Q1 | $16.6K | Buy |
3,162
+2,798
| +769% | +$16K | ﹤0.01% | 3946 |
|
|
2018
Q4 | $1.62K | Sell |
364
-87
| -19% | -$477 | ﹤0.01% | 3837 |
|
|
2018
Q3 | $3.64K | Sell |
451
-259
| -36% | -$1.85K | ﹤0.01% | 4156 |
|
|
2018
Q2 | $4.98K | Sell |
710
-1,796
| -72% | -$17.6K | ﹤0.01% | 4104 |
|
|
2018
Q1 | $35.7K | Buy |
2,506
+32
| +1% | +$340 | ﹤0.01% | 3721 |
|
|
2017
Q4 | $21.7K | Buy |
2,474
+1,818
| +277% | +$18K | ﹤0.01% | 3947 |
|
|
2017
Q3 | $7.67K | Buy |
656
+178
| +37% | +$2.18K | ﹤0.01% | 3933 |
|
|
2017
Q2 | $6.68K | Buy |
478
+469
| +5,211% | +$5.36K | ﹤0.01% | 4009 |
|
|
2017
Q1 | $123 | Sell |
9
-56
| -86% | -$582 | ﹤0.01% | 3992 |
|
|
2016
Q4 | $466 | Sell |
65
-256
| -80% | -$2.81K | ﹤0.01% | 4063 |
|
|
2016
Q3 | $4.87K | Buy |
321
+135
| +73% | +$1.78K | ﹤0.01% | 3393 |
|
|
2016
Q2 | $1.83K | Buy |
+186
| New | +$2.55K | ﹤0.01% | 3454 |
|
Other funds holding SNDX
EP
HRCM
KCM
BNP Paribas Financial Markets's SNDX Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its Syndax Pharmaceuticals (SNDX) stake by 19% in Q2 2026, selling an estimated $162K and leaving 32,601 shares worth $713K. The position accounts for ﹤0.01% of the portfolio, ranked #3551.
BNP Paribas Financial Markets first reported a position in SNDX in Q2 2016 and has held it in 41 quarters since. The position peaked at $9.23M in Q3 2025. 218 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.
- BNP Paribas Financial Markets held 32,601 shares of Syndax Pharmaceuticals worth $713K as of Q2 2026.
- BNP Paribas Financial Markets sold 7,780 Syndax Pharmaceuticals shares in Q2 2026, an estimated $162K.
- Syndax Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3551 holding.
- BNP Paribas Financial Markets first reported a position in Syndax Pharmaceuticals in Q2 2016 and has held it in 41 quarters since.
- BNP Paribas Financial Markets's Syndax Pharmaceuticals position peaked at $9.23M in Q3 2025.
- 218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.